Key Points
- Glaukos COO Joseph Gilliam sold 60,000 shares at an average price of $179.74, generating approximately $10.8 million. His direct ownership fell 45.25% to 72,588 shares.
- Glaukos shares opened at $189.09, near their 52-week high of $189.69, after the company reported quarterly revenue of $185.61 million—up 49.6% year over year and above analyst expectations.
- Analysts remain broadly positive, with 12 Buy ratings, two Holds and one Sell; the stock carries a “Moderate Buy” consensus and an average price target of $177.33.
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 60,000 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares of the company's stock, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Glaukos Trading Up 1.3%
Shares of GKOS opened at $189.09 on Friday. The stock has a market capitalization of $11.15 billion, a PE ratio of -58.18 and a beta of 0.78. The company's fifty day moving average is $150.03 and its 200 day moving average is $128.97. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $189.69.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. During the same quarter last year, the business earned ($0.24) earnings per share. Glaukos's quarterly revenue was up 49.6% compared to the same quarter last year. Sell-side analysts expect that Glaukos Corporation will post -0.35 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Glaukos
Institutional investors have recently made changes to their positions in the company. Allworth Financial LP purchased a new position in shares of Glaukos during the 2nd quarter worth about $28,000. First Horizon Corp raised its position in Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 223 shares during the period. Los Angeles Capital Management LLC bought a new stake in Glaukos in the fourth quarter worth about $28,000. Larson Financial Group LLC lifted its stake in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 132 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 226 shares during the last quarter. Institutional investors own 99.04% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently commented on GKOS shares. Citigroup increased their price target on shares of Glaukos from $175.00 to $188.00 and gave the company a "buy" rating in a report on Thursday, July 30th. JPMorgan Chase & Co. upped their price objective on Glaukos from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, April 30th. Needham & Company LLC raised their price objective on Glaukos from $150.00 to $201.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. HC Wainwright lifted their target price on Glaukos from $168.00 to $195.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Finally, Piper Sandler reissued an "overweight" rating and set a $195.00 target price (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $177.33.
View Our Latest Stock Report on GKOS
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
